Expression of c-Myc was associated with reduced cancer specific survival in rectal cancer (P = .003, HR = 3.714, 95% CI for HR [1.568;8.797], while overexpression of c-Myc in colon adenocarcinomas not treated with adjuvant chemotherapy was associated with higher cancer specific survival (P = .028, HR = 0.353, 95% CI for HR [0.140;0.893]). This evidence concerns the gene MYC and colon adenocarcinoma.